CD274 and cancer: Among the broad spectrum of immune checkpoint blockade therapies, the outstanding success story unfolds with anti-PD-1/PD-L1 therapy, a therapeutic approach that has been approved for the treatment of a diverse array of cancers spanning hematologic, cutaneous, pulmonary, hepatic, vesical, and renal malignancies.